(Q34193382)

31 July 2017

1 reference

title

Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. (English)

1 reference

31 July 2017

1 reference

2

Brogden RN

1 reference

31 July 2017

Richards DM

1

1 reference

31 July 2017

publication date

1 February 1985

1 reference

31 July 2017

1 reference

31 July 2017

volume

29

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

105-161

1 reference

Clinical evaluation of ceftazidime in the field of pediatrics

31 July 2017

cites work

1 reference

12 December 2020

Ceftazidime in the treatment of complicated respiratory and urinary tract infections

1 reference

12 December 2020

A multicentre prospective randomized trial comparing ceftazidime with cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia

1 reference

12 December 2020

The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers

1 reference

12 December 2020

Pharmacokinetics of ceftazidime in patients with renal insufficiency

1 reference

12 December 2020

Ceftazidime disposition in acute and stable cystic fibrosis

1 reference

12 December 2020

Comparative pharmacokinetics of ceftazidime and moxalactam

1 reference

12 December 2020

Investigation of the beta-lactamase stability of ceftazidime and eight other new cephalosporin antibiotics.

1 reference

12 December 2020

Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus

1 reference

12 December 2020

Novel resistance selected by the new expanded-spectrum cephalosporins: a concern.

1 reference

12 December 2020

[Clinical studies of ceftazidime in the pediatric field]

1 reference

12 December 2020

Clinical studies on ceftazidime in surgery in Japan

1 reference

12 December 2020

Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid

1 reference

12 December 2020

Comparative Multiple-Dose Pharmacokinetics of Cefotaxime, Moxalactam, and Ceftazidime

1 reference

12 December 2020

Cephalosporins in cutaneous infections. A prospective comparison of two dosage regimens of ceftazidime for therapy of skin and skin structure infections

1 reference

12 December 2020

Open study of ceftazidime in serious infections due to multiply-resistant bacteria

1 reference

12 December 2020

In-vitro activity and beta-lactamase stability of Sch 29482, a penem antibiotic. Comparisons with ceftazidime and moxalactam

1 reference

12 December 2020

Ceftazidime, ceftizoxime, cefotaxime and HR 221 in experimental chronic Escherichia coli pyelonephritis in rats

1 reference

12 December 2020

Ceftazidime in patients with pseudomonas infections

1 reference

12 December 2020

Ceftazidime in cystic fibrosis

1 reference

12 December 2020

Treatment of lower respiratory tract infections with ceftazidime

1 reference

12 December 2020

In-vitro studies with ceftazidime against aerobic gram-negative bacilli and Bacteroides fragilis group.

1 reference

12 December 2020

Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates

1 reference

12 December 2020

Ceftazidime, a new cephalosporin in the treatment of complicated urinary tract infections: a comparative study with tobramycin

1 reference

12 December 2020

A study of cefoxitin, moxalactam, and ceftazidime kinetics in pregnancy

1 reference

12 December 2020

Activities of eight new beta-lactam antibiotics and seven antibiotic combinations against Neisseria meningitidis

1 reference

12 December 2020

In vitro activity of ceftazidime (GR 20263) and other β-lactam antibiotics against Haemophilus influenzae

1 reference

12 December 2020

Ceftazidime as a single agent in the management of children with fever and neutropenia

1 reference

12 December 2020

Successful treatment of Pseudomonas aeruginosa meningitis with ceftazidime

1 reference

12 December 2020

In-vivo properties of SQ 26,776

1 reference

12 December 2020

Ceftazidime: pharmacokinetics in young volunteers versus elderly patients and therapeutic efficacy with complicated urinary tract infections

1 reference

12 December 2020

Activity of β-lactamase inhibitors in combination with new β-lactam antibiotics against resistant gram-negative organisms

1 reference

12 December 2020

The effect of n-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative gram-negative rods, Aeromonas, Plesiomonas and Enterobacter agglomerans

1 reference

12 December 2020

The current state of cephalosporin antibiotics: microbiological aspects.

1 reference

12 December 2020

Comparative In Vitro Activity of New Beta-Lactam Antibiotics Against Anaerobic Bacteria

1 reference

12 December 2020

Ceftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosa.

1 reference

12 December 2020

Ceftazidime and renal function

1 reference

12 December 2020

A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients

1 reference

12 December 2020

Comparison of the in-vitro activities of ceftazidime and new cephalosporins against 107 strains of Pseudomonas aeruginosa and 249 strains of cefazolin-resistant Enterobacteriaceae

1 reference

12 December 2020

Basic and clinical studies on ceftazidime in the field of obstetrics and gynecology

1 reference

12 December 2020

Ceftazidime (GR 20263), a new cephalosporin derivative with excellent activity against Pseudomonas and Enterobacteriaceae

1 reference

12 December 2020

[Monotherapy of systematic Pseudomonas aeruginosa infections with ceftazidime. The causes of therapeutic failures]

1 reference

12 December 2020

Fundamental and clinical studies of ceftazidime in the field of obstetrics and gynecology

1 reference

12 December 2020

Third-Generation and Investigational Cephalosporins: II. Microbiologic Review and Clinical Summaries

1 reference

12 December 2020

Comparative in vitro study in new cephalosporins

1 reference

12 December 2020

The distribution of Klebsiella pneumoniae serotypes from different sources and their sensitivity to cephalosporins

1 reference

12 December 2020

In vitro comparison of cefotetan with five other cephalosporins against nosocomial pathogens.

1 reference

12 December 2020

Yersinia enterocolitica: comparative in vitro activities of seven new beta-lactam antibiotics

1 reference

12 December 2020

Effect of Broad-Spectrum Cephalosporins on the Microbial Flora of Recipients

1 reference

12 December 2020

[Clinical experience with ceftazidime in the infectious disease of children].

1 reference

12 December 2020

Penetration of ceftazidime in human pericardial fluid and lung tissue

1 reference

12 December 2020

Pharmacokinetics of ceftazidime in newborn infants

1 reference

12 December 2020

Pseudomonas aeruginosa isolates with modified beta-lactamase inducibility: effects on beta-lactam sensitivity

1 reference

12 December 2020

Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections

1 reference

12 December 2020

[Fundamental and clinical studies of ceftazidime in the field of pediatrics].

1 reference

12 December 2020

The in vitro activity of ceftazidime against resistant clinical isolates

1 reference

12 December 2020

Bactericidal activities of chloramphenicol and eleven other antibiotics against Salmonella spp

1 reference

12 December 2020

Ceftazidime treatment in intensive care patients

1 reference

12 December 2020

Comparative activity in vitro of ceftazidime and nine other antibacterial agents

1 reference

12 December 2020

Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae

1 reference

12 December 2020

[Fundamental and clinical studies on ceftazidime in the field of obstetrics and gynecology]

1 reference

12 December 2020

Ceftazidime: in vitro comparison with cephalothin, cefuroxime, and netilmicin. A Norwegian study

1 reference

12 December 2020

[Combined in vitro effect of new betalactam antibiotics and aminoglycosides against Pseudomonas aeruginosa ]

1 reference

12 December 2020

Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response

1 reference

12 December 2020

[Clinical evaluation of ceftazidime in the treatment of pediatric infections]

1 reference

12 December 2020

Ceftazidime compared to tobramycin and ticarcillin in immunocompromised haematological patients

1 reference

12 December 2020

Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats

1 reference

12 December 2020

Pharmacokinetic studies on ceftazidime in the obstetrical and gynecological field

1 reference

12 December 2020

Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin.

1 reference

12 December 2020

Comparison of ceftazidime concentrations in bile and serum

1 reference

12 December 2020

Effect of clavulanic acid on the activities of ten beta-lactam agents against members of the Bacteroides fragilis group

1 reference

12 December 2020

A comparison of ceftazidime and tobramycin in the treatment of complicated urinary tract infections

1 reference

12 December 2020

GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity

1 reference

12 December 2020

Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests

1 reference

12 December 2020

Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients

1 reference

12 December 2020

[Laboratory and clinical studies of ceftazidime in the pediatric field]

1 reference

12 December 2020

Evaluation of ceftazidime in the treatment of severe bacterial infection

1 reference

12 December 2020

Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis

1 reference

12 December 2020

In vitro activity and beta-lactamase stability of cefmenoxime

1 reference

12 December 2020

The penetration of ceftazidime into extravascular fluid

1 reference

12 December 2020

Ceftazidime in clinical practice -- A summary

1 reference

12 December 2020

Ceftazidime in the treatment of febrile immunosuppressed children

1 reference

12 December 2020

[Comparison of in vitro bacteriostatic effect of five betalactamins against Pseudomonas aeruginosa (author's transl)]

1 reference

12 December 2020

The antibacterial activity in vitro and β-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides

1 reference

12 December 2020

In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime

1 reference

12 December 2020

Good antimicrobial prescribing. Clinical uses of cephalosporins

1 reference

12 December 2020

[Fundamental and clinical studies on ceftazidime in the field of pediatrics]

1 reference

12 December 2020

Experience with ceftazidime in obstetrics and gynaecology in Japan

1 reference

12 December 2020

Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa

1 reference

12 December 2020

Tissue penetration and clinical effects of ceftazidime in the field of obstetrics and gynecology

1 reference

12 December 2020

Comparative in vitro activity of cefodizime, ceftazidime, aztreonam, and other selected antimicrobial agents against Neisseria gonorrhoeae

1 reference

12 December 2020

In vitro activity and beta-lactamase stability of a monobactam, SQ 26,917, compared with those of aztreonam and other agents

1 reference

12 December 2020

Pharmacokinetics and bacteriological effect of ceftazidime in experimental Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli meningitis

1 reference

12 December 2020

Activity of ceftazidime against Pseudomonas aeruginosa from bacteraemic and fibrocystic patients

1 reference

12 December 2020

Determination of ceftazidime in biological fluids by using high-pressure liquid chromatography

1 reference

12 December 2020

Clinical pharmacology of ceftazidime in paediatrics

1 reference

12 December 2020

Moxalactam (Latamoxef) A Review of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use

1 reference

12 December 2020

GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae

1 reference

12 December 2020

Experience with ceftazidime in the field of obstetrics and gynecology

1 reference

12 December 2020

In-vitro activity of ceftizoxime against anaerobic bacteria and comparison with other cephalosporins

1 reference

12 December 2020

Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis

1 reference

12 December 2020

Ceftazidime: a new approach in the treatment of moderate and severe infections

1 reference

12 December 2020

Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis

1 reference

12 December 2020

Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms

1 reference

12 December 2020

Ceftazidime, as a single antibiotic, in the treatment of multi-resistant Gram-negative infections in intensive care

1 reference

12 December 2020

Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds

1 reference

12 December 2020

Comparison of in-vitro activity of latamoxef (moxalactam) and ceftazidime against Pseudomonas and Enterobacteriaceae resistant to first generation cephalosporins

1 reference

12 December 2020

In vitro activity of temocillin (BRL 17421), a novel beta-lactam antibiotic

1 reference

12 December 2020

Ceftizoxime and other third-generation cephalosporins: structure-activity relationships

1 reference

12 December 2020

Ceftazidime in the therapy of serious Gram-negative bacillary infections

1 reference

12 December 2020

The pharmacokinetics of ceftazidime in normal and impaired renal function

1 reference

12 December 2020

Evaluation of ceftazidime in the treatment of severe infection.

1 reference

12 December 2020

Activity of ceftazidime and newer antibiotics against Gram-negative bacilli

1 reference

12 December 2020

Experience with ceftazidime in cystic fibrosis

1 reference

12 December 2020

Comparison of the β-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa

1 reference

12 December 2020

The in-vitro activity of ceftazidime compared with that of other cephalosporins

1 reference

12 December 2020

Disk agar diffusion susceptibility testing with 30-micrograms ceftazidime disks: confirmation of interpretive breakpoints and quality control guidelines

1 reference

12 December 2020

Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections

1 reference

12 December 2020

The activity in vitro of ceftazidime (GR 20263) and moxalactam (LY 127935) against Gram-negative bacteria from hospital patients

1 reference

12 December 2020

Influence of probenecid on serum and subcutaneous tissue fluid concentrations of benzylpenicillin and ceftazidime in human volunteers

1 reference

12 December 2020

The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin

1 reference

12 December 2020

[Laboratory and clinical studies on ceftazidime in the field of pediatrics]

1 reference

12 December 2020

Susceptibility of ceftazidime and other cephalosporins to a range of beta-lactamases and their potential as inducing agents

1 reference

12 December 2020

[Comparative in vitro activity of 5 beta-lactams (cefoperazone, cefsulodin, ceftazidime, azthreonam, N-formimidoyl-thienamycin) on 90 strains of Pseudomonas aeruginosa with various levels of resistance to ticarcillin]

1 reference

12 December 2020

Clinical and bacteriological evaluation of ceftazidime (GR 20263) as an antipseudomonal drug

1 reference

12 December 2020

Penetration of eight beta-lactam antibiotics into the peritoneal fluid. A pharmacokinetic investigation

1 reference

12 December 2020

Comparative study of the effects of ceftazidime compared with tobramycin plus cefamandole in the treatment of gall bladder empyema

1 reference

12 December 2020

Ceftazidime in severe infections: a Swiss multicentre study

1 reference

12 December 2020

The new beta-lactamase-stable cephalosporins

1 reference

12 December 2020

An evaluation of the activity of cephalosporins against Pseudomonas aeruginosa

1 reference

12 December 2020

[Synergistic activity between ticarcillin, azlocillin, cefsulodin, ceftazidime and tobramycin or amikacin against Pseudomonas aeruginosa (author's transl)]

1 reference

12 December 2020

Serum bactericidal activity of cefoperazone and ceftazidime at increasing dosages against Pseudomonas aeruginosa.

1 reference

12 December 2020

Ceftazidime or gentamicin plus benzylpenicillin in neonates less than forty-eight hours old

1 reference

12 December 2020

Pharmacokinetics of ceftazidime in male and female volunteers

1 reference

12 December 2020

Ceftazidime versus tobramycin/ticarcillin in treating hospital acquired pneumonia and bacteremia

1 reference

12 December 2020

Reduced sensitivity to beta-lactam antibiotics arising during ceftazidime treatment of Pseudomonas aeruginosa infections

1 reference

12 December 2020

A comparative study of the efficacy of ceftazidime versus cefazolin and tobramycin in patients with acute exacerbations of chronic bronchitis

1 reference

12 December 2020

A random comparative trial of 0.25, 0.5 and 1.0 g ceftazidime twice daily in urinary tract infection

1 reference

12 December 2020

Comparative susceptibility of Pseudomonas aeruginosa to four cephalosporins

1 reference

12 December 2020

The activity of ceftazidime, other beta-lactams, and aminoglycosides against Pseudomonas aeruginosa.

1 reference

12 December 2020

Clinical studies on ceftazidime in the pediatric field

1 reference

12 December 2020

In vitro activities of new beta-lactam antibiotics against Acinetobacter spp.

1 reference

12 December 2020

Comparative in-vitro activity of ceftazidime (GR-20263) and other beta-lactamase stable cephalosporins against anaerobic bacteria

1 reference

12 December 2020

Correlation of in vitro activities of cephalothin and ceftazidime with their efficacies in the treatment of Staphylococcus aureus endocarditis in rabbits

1 reference

12 December 2020

Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria.

1 reference

12 December 2020

Bactericidal activity of ceftazidime against Pseudomonas aeruginosa under conditions simulating serum pharmacokinetic

1 reference

12 December 2020

Perioperative use of ceftazidime as a prophylactic agent in transurethral surgery

1 reference

12 December 2020

A preliminary pharmacokinetic studyn of ceftazidime in premature, new born and small infants

1 reference

12 December 2020

The pharmacokinetics and tissue penetration of ceftazidime and cefamandole in healthy volunteers.

1 reference

12 December 2020

Penetration of ceftazidime into cerebrospinal fluid of patients with bacterial meningitis

1 reference

12 December 2020

Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics

1 reference

12 December 2020

Antibiotic activity and synergism of ceftazidime and netilmicin against gram-negative pathogenic bacteria

1 reference

12 December 2020

Ceftazidime: comparative in-vitro study

1 reference

12 December 2020

[Fundamental and clinical studies on ceftazidime in the field of paediatrics]

1 reference

12 December 2020

The treatment of bone infections with ceftazidime

1 reference

12 December 2020

Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora

1 reference

12 December 2020

Ceftazidime in the treatment of chronic suppurative otitis media in children

1 reference

12 December 2020

The susceptibility of nosocomial pathogens to ceftazidime

1 reference

12 December 2020

Studies on absorption, distribution, metabolism and excretion of ceftazidime in Japan

1 reference

12 December 2020

[Fundamental and clinical studies of ceftazidime in the pediatric field]

1 reference

12 December 2020

Distribution of ceftazidime in ascitic fluid

1 reference

12 December 2020

In vitro activity of newer β-lactam agents in combination with amikacin against Pseudomonas aeruginosa, Klebsiella pneumoniae, and Serratia marcescens

1 reference

12 December 2020

The in-vitro activity of ceftazidime against clinically important pathogens.

1 reference

12 December 2020

Ceftazidime--a significant advance in the treatment of cystic fibrosis

1 reference

12 December 2020

Susceptibility of Propionibacterium acnes clinical isolates to 22 antimicrobial agents

1 reference

12 December 2020

Clinical experience with ceftazidime in urology in Japan

1 reference

12 December 2020

Simultaneous comparison of three methods for assessing ceftazidime penetration into extravascular fluid

1 reference

12 December 2020

Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients

1 reference

12 December 2020

Comparative in vitro study of SQ26,776.

1 reference

12 December 2020

Characteristics of a beta-lactamase produced by Clostridium butyricum

1 reference

12 December 2020

Activity of Cefoperazone Against Ampicillin-Resistant Bacteria in Agar and Broth Dilution Tests

1 reference

12 December 2020

Ceftazidime in cystic fibrosis: clinical, microbiological and immunological studies

1 reference

12 December 2020

The antimicrobial susceptibility of anaerobic bacteria in a London teaching hospital.

1 reference

12 December 2020

Ceftazidime levels in human breast milk

1 reference

12 December 2020

Ceftazidime Concentrations in Human Aqueous Humor

1 reference

12 December 2020

[Clinical study on ceftazidime in the field of pediatrics]

1 reference

12 December 2020

Renal disposition of ceftazidime illustrated by interferences by probenecid, furosemide, and indomethacin in rabbits

1 reference

12 December 2020

In vitro activity of new cephalosporins against multi-resistant gram-negative bacteria

1 reference

12 December 2020

Clinical and pharmacokinetic evaluation of ceftazidime in children

1 reference

12 December 2020

Comparative in vitro activities of third-generation cephalosporins

1 reference

12 December 2020

Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method

1 reference

12 December 2020

Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis

1 reference

12 December 2020

Third-generation cephalosporins in the treatment of pneumonia due to Pseudomonas aeruginosa in guinea pigs.

1 reference

12 December 2020

Ceftazidime: therapeutic results in various infections and kinetic studies.

1 reference

12 December 2020

Inoculum effect of new beta-lactam antibiotics on Pseudomonas aeruginosa

1 reference

12 December 2020

Penetration of ceftazidime into serum, myometrium, endometrium, salpinges and subcutaneous tissue

1 reference

12 December 2020

High-pressure liquid chromatographic analysis of ceftazidime in serum and urine

1 reference

12 December 2020

Cephalosporin-resistance in the Bacteroides fragilis group and the effect of clavulanic acid

1 reference

12 December 2020

Ceftazidime in the treatment of lower respiratory tract infection

1 reference

12 December 2020

Comparative susceptibilities of penicillin-resistant pneumococci to co-trimoxazole, vancomycin, rifampicin and fourteen beta-lactam antibiotics

1 reference

12 December 2020

Comparative in-vitro activity of cefsulodin and ceftazidime against ticarcillin-resistant Pseudomonas aeruginosa

1 reference

12 December 2020

The microbiological assay of ceftazidime

1 reference

12 December 2020

Randomized comparison of ceftazidime versus clindamycin-tobramycin in the treatment of obstetrical and gynecological infections

1 reference

12 December 2020

Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime

1 reference

12 December 2020

Pharmacokinetics of ceftazidime in renal failure

1 reference

12 December 2020

The evaluation of ceftazidime in the treatment of bacterial infections in eighty seriously ill patients

1 reference

12 December 2020

Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis

1 reference

12 December 2020

Ceftazidime activity in experimental pseudomonas pyelonephritis in rats

1 reference

12 December 2020

Clinical evaluation of ceftazidime in Japan

1 reference

12 December 2020

Clinical use of the new beta-lactam antimicrobial drugs. Practical considerations for physicians, microbiology laboratories, pharmacists, and formulary committees

1 reference

12 December 2020

Serratia marcescens endocarditis treated with ceftazidime. A case report

1 reference

12 December 2020

Influence of bacterial beta-lactamase production on susceptibility in agar or broth to new cephalosporins.

1 reference

12 December 2020

Penetration of ceftazidime into human tissue in patients undergoing cardiac surgery

1 reference

12 December 2020

In-vitro studies with ceftazidime

1 reference

12 December 2020

The pharmacokinetic behaviour of ceftazidime in man and the relationship between serum levels and the in vitro susceptibility of clinical isolates

1 reference

12 December 2020

Assay of ceftazidime in biological fluids using high-pressure liquid chromatography.

1 reference

12 December 2020

In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp

1 reference

12 December 2020

Ceftazidime in Gram-negative infections: three case reports

1 reference

12 December 2020

Ceftazidime and cefamandole in the treatment of pneumonia

1 reference

12 December 2020

Selection of variants of Gram-negative bacteria with elevated production of type 1 beta-lactamase

1 reference

12 December 2020

In vitro activity of ceftazidime, cefotaxime and piperacillin against multi-resistant gram-negative bacteria tested with a modified agar dilution method

1 reference

12 December 2020

Clinical evaluation of ceftazidime in paediatrics

1 reference

12 December 2020

In-vitro activity of ceftazidime against Pseudomonas aeruginosa: and its stability to pseudomonal beta-lactamases.

1 reference

12 December 2020

Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins

1 reference

12 December 2020

[Comparative bactericidal activity of beta-lactam-aminoglycoside combinations against Pseudomonas aeruginosa]

1 reference

12 December 2020

Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia

1 reference

12 December 2020

[Fundamental and clinical studies on ceftazidime in the field of pediatrics]

1 reference

12 December 2020

Ceftazidime in septicaemia

1 reference

12 December 2020

Comparative in-vitro activity of ceftazidime (GR 20263) and other beta-lactamase stable cephalosporins against pseudomonas. Effect of inoculum size and divalent cation supplementation

1 reference

12 December 2020

Successful Treatment of Melioidosis Caused by a Multiresistant Strain in an Immunocompromised Host with Third Generation Cephalosporins1

1 reference

12 December 2020

Ceftazidime in the treatment of pediatric patients with severe urinary tract infections due to Pseudomonas spp

1 reference

12 December 2020

In vitro antibacterial activity of the combination of clindamycin and ceftazidime

1 reference

12 December 2020

Ceftazidime therapy of serious bacterial infections

1 reference

12 December 2020

Pharmacokinetics and efficacy of ceftazidime in experimental Haemophilus influenzae b meningitis.

1 reference

12 December 2020

Ceftazidime: pharmacokinetics in patients and effects on the renal function

1 reference

12 December 2020

Comparative activities of 13 beta-lactam antibiotics

1 reference

12 December 2020

In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa

1 reference

12 December 2020

Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli

1 reference

12 December 2020

Multiple dose pharmacokinetics and therapeutic results with ceftazidime

1 reference

12 December 2020

Resistance to cephalosporins among gentamicin-resistant klebsiellae.

1 reference

12 December 2020

Lack of Interference of Five New Beta-Lactam Antibiotics with Serum Creatinine Determination

1 reference

12 December 2020

[Cefoperazone, cefsulodin and ceftazidime--3 cephalosporins active against Pseudomonas in comparison with their monobactam analogs]

1 reference

12 December 2020

Fundamental and clinical studies of ceftazidime, a new cephem antibiotic in the field of pediatrics

1 reference

12 December 2020

Pharmacokinetic studies of ceftazidime in serum, bone, bile, tissue fluid and peritoneal fluid

1 reference

12 December 2020

Ceftazidime: aspects of efficacy and tolerance

1 reference

12 December 2020

Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli

1 reference

12 December 2020

Comparative in vitro activity of first, second and third generation cephalosporins

1 reference

12 December 2020

Ceftazidime therapy for serious infections

1 reference

12 December 2020

The in-vitro properties of ceftazidime

1 reference

12 December 2020

[Basic and clinical studies on ceftazidime in the pediatric field].

1 reference

12 December 2020

10.2165/00003495-198529020-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1051308330

0 references

1 reference